Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's ...
The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
Zacks Investment Research on MSN1d
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's DiseaseJohnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, ...
Spring House, Pennsylvania Wednesday, March 19, 2025, 14:00 Hrs [IST] ...
The other area that we think is sort of an area of unmet need is being able to potentially offer treatment ... Nipocalimab is actually being developed across 3 segments of autoantibody-driven ...
Johnson & Johnson (NYSE:JNJ) said on Tuesday that it received U.S. FDA's Fast Track designation for nipocalimab to treat adult patients with moderate-to-severe Sjögren's disease. In November last year ...
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results ...
FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...
House: Johnson & Johnson has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback